301 related articles for article (PubMed ID: 28104509)
1. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
[TBL] [Abstract][Full Text] [Related]
2. Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.
Villa P; Lassandro AP; Amar ID; Vacca L; Moruzzi MC; Ferrandina G; Terribile D; Masetti R; Scambia G
Menopause; 2016 Jan; 23(1):33-9. PubMed ID: 26308233
[TBL] [Abstract][Full Text] [Related]
3. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
5. Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study.
Pedersini R; Cosentini D; Rinaudo L; Zamparini M; Ulivieri FM; di Mauro P; Maffezzoni F; Monteverdi S; Vena W; Laini L; Amoroso V; Simoncini EL; Farina D; Mazziotti G; Berruti A
Bone Rep; 2023 Jun; 18():101654. PubMed ID: 36700242
[TBL] [Abstract][Full Text] [Related]
6. The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy.
Monteverdi S; Pedersini R; Gallo F; Maffezzoni F; Dalla Volta A; Di Mauro P; Turla A; Vassalli L; Ardine M; Formenti AM; Simoncini EL; Giustina A; Maroldi R; Amoroso V; Berruti A
JBMR Plus; 2021 Feb; 5(2):e10440. PubMed ID: 33615109
[TBL] [Abstract][Full Text] [Related]
7. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Gonzalez-Rodriguez E; Aubry-Rozier B; Stoll D; Zaman K; Lamy O
Breast Cancer Res Treat; 2020 Jan; 179(1):153-159. PubMed ID: 31598815
[TBL] [Abstract][Full Text] [Related]
8. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
Mazziotti G; Formenti AM; Frara S; Olivetti R; Banfi G; Memo M; Maroldi R; Giubbini R; Giustina A
J Clin Endocrinol Metab; 2018 Mar; 103(3):956-964. PubMed ID: 29121201
[TBL] [Abstract][Full Text] [Related]
9. Vertebral fracture prevalence among Greek healthy middle-aged postmenopausal women: association with demographics, anthropometric parameters, and bone mineral density.
Lambrinoudaki I; Flokatoula M; Armeni E; Pliatsika P; Augoulea A; Antoniou A; Alexandrou A; Creatsa M; Panoulis C; Dendrinos S; Papacharalambous X
Spine J; 2015 Jan; 15(1):86-94. PubMed ID: 25106754
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and determinants of radiological vertebral fractures in patients with Klinefelter syndrome.
Vena W; Pizzocaro A; Indirli R; Amer M; Maffezzoni F; Delbarba A; Leonardi L; Balzarini L; Ulivieri FM; Ferlin A; Mantovani G; Lania AG; Ferrante E; Mazziotti G
Andrology; 2020 Nov; 8(6):1699-1704. PubMed ID: 32558374
[TBL] [Abstract][Full Text] [Related]
11. Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer.
Lee SJ; Kim KM; Brown JK; Brett A; Roh YH; Kang DR; Park BW; Rhee Y
Calcif Tissue Int; 2015 Dec; 97(6):551-9. PubMed ID: 26232103
[TBL] [Abstract][Full Text] [Related]
12. Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes in parathyroid hormone.
Sosa M; Jódar E; Saavedra P; Navarro MC; Gómez de Tejada MJ; Martín A; Peña P; Gómez J
Eur J Intern Med; 2008 Jan; 19(1):51-6. PubMed ID: 18206602
[TBL] [Abstract][Full Text] [Related]
13. Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.
Mazziotti G; Pedersini R; Vena W; Cosentini D; Carrone F; Pigni S; Simoncini EL; Torrisi R; Zambelli A; Farina D; Balzarini L; Lania AG; Berruti A
Calcif Tissue Int; 2022 Nov; 111(5):466-474. PubMed ID: 35902384
[TBL] [Abstract][Full Text] [Related]
14. Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency.
Mazziotti G; Doga M; Frara S; Maffezzoni F; Porcelli T; Cerri L; Maroldi R; Giustina A
Endocrine; 2016 Apr; 52(1):103-10. PubMed ID: 26433736
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
16. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
[TBL] [Abstract][Full Text] [Related]
17. Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.
Catalano A; Gaudio A; Agostino RM; Morabito N; Bellone F; Lasco A
J Endocrinol Invest; 2019 Nov; 42(11):1337-1343. PubMed ID: 31127591
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy.
Bouvard B; Hoppé E; Soulié P; Georgin-Mege M; Jadaud E; Abadie-Lacourtoisie S; Petit Le Manac'h A; Laffitte A; Levasseur R; Audran M; Chappard D; Legrand E
Ann Oncol; 2012 May; 23(5):1151-1156. PubMed ID: 21903604
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
[TBL] [Abstract][Full Text] [Related]
20. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
